IBM (IBM) Expands AI Push With Launch of watsonx Orchestrate for Enterprise Agents
IBM said the new solution supports agents for domains like human resources, procurement and sales, automating tasks such as time-off management, vendor workflows, and lead qualification. The platform integrates with more than 80 enterprise applications, including Microsoft, Adobe, Oracle and Salesforce.
The company is also releasing a no-code automation studio that allows users to build agents in under five minutes, along with a pro-code Agent Development Kit for developers using frameworks like CrewAI and LangGraph. An Agent Catalog with more than 150 tools is expected to support partner-built agents and integrations with collaboration tools such as Slack.
IBM highlighted that watsonx Orchestrate includes agent orchestration and observability features to ensure effective coordination and responsible AI deployment. The system is built to support Model Context Protocol for broader interoperability, allowing companies to integrate agents with thousands of existing tools and APIs.
The company said it expects watsonx Orchestrate to serve as the foundation for next-generation enterprise automation, helping businesses scale agent-based solutions without vendor lock-in.
This article first appeared on GuruFocus.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
22 minutes ago
- Yahoo
10x Genomics (NASDAQ:TXG) Reports Upbeat Q2, Stock Soars
Biotech company 10x Genomics (NASDAQ:TXG) beat Wall Street's revenue expectations in Q2 CY2025, with sales up 12.9% year on year to $172.9 million. On the other hand, next quarter's revenue guidance of $142 million was less impressive, coming in 1.5% below analysts' estimates. Its GAAP profit of $0.28 per share was significantly above analysts' consensus estimates. Is now the time to buy 10x Genomics? Find out in our full research report. 10x Genomics (TXG) Q2 CY2025 Highlights: Revenue: $172.9 million vs analyst estimates of $139.5 million (12.9% year-on-year growth, 24% beat) EPS (GAAP): $0.28 vs analyst estimates of -$0.37 (significant beat) Revenue Guidance for Q3 CY2025 is $142 million at the midpoint, below analyst estimates of $144.2 million Operating Margin: 17.4%, up from -27.3% in the same quarter last year Market Capitalization: $1.58 billion Company Overview Founded in 2012 by scientists seeking to overcome limitations in traditional biological research methods, 10x Genomics (NASDAQ:TXG) develops instruments, consumables, and software that enable researchers to analyze biological systems at single-cell resolution and spatial context. Revenue Growth A company's long-term sales performance is one signal of its overall quality. Any business can put up a good quarter or two, but many enduring ones grow for years. Over the last five years, 10x Genomics grew its sales at an impressive 20.7% compounded annual growth rate. Its growth beat the average healthcare company and shows its offerings resonate with customers. Long-term growth is the most important, but within healthcare, a half-decade historical view may miss new innovations or demand cycles. 10x Genomics's recent performance shows its demand has slowed significantly as its annualized revenue growth of 6.5% over the last two years was well below its five-year trend. We can dig further into the company's revenue dynamics by analyzing its most important segment, Consumables. Over the last two years, 10x Genomics's Consumables revenue (recurring orders) averaged 3.7% year-on-year growth. This segment has lagged the company's overall sales. This quarter, 10x Genomics reported year-on-year revenue growth of 12.9%, and its $172.9 million of revenue exceeded Wall Street's estimates by 24%. Company management is currently guiding for a 6.4% year-on-year decline in sales next quarter. Looking further ahead, sell-side analysts expect revenue to decline by 7.6% over the next 12 months, a deceleration versus the last two years. This projection is underwhelming and indicates its products and services will see some demand headwinds. Today's young investors likely haven't read the timeless lessons in Gorilla Game: Picking Winners In High Technology because it was written more than 20 years ago when Microsoft and Apple were first establishing their supremacy. But if we apply the same principles, then enterprise software stocks leveraging their own generative AI capabilities may well be the Gorillas of the future. So, in that spirit, we are excited to present our Special Free Report on a profitable, fast-growing enterprise software stock that is already riding the automation wave and looking to catch the generative AI next. Operating Margin Although 10x Genomics was profitable this quarter from an operational perspective, it's generally struggled over a longer time period. Its expensive cost structure has contributed to an average operating margin of negative 42.4% over the last five years. Unprofitable healthcare companies require extra attention because they could get caught swimming naked when the tide goes out. It's hard to trust that the business can endure a full cycle. On the plus side, 10x Genomics's operating margin rose over the last five years, as its sales growth gave it operating leverage. Zooming in on its more recent performance, we can see the company's trajectory is intact as its margin has also increased by 15.8 percentage points on a two-year basis. This quarter, 10x Genomics generated an operating margin profit margin of 17.4%, up 44.7 percentage points year on year. This increase was a welcome development and shows it was more efficient. Earnings Per Share Revenue trends explain a company's historical growth, but the long-term change in earnings per share (EPS) points to the profitability of that growth – for example, a company could inflate its sales through excessive spending on advertising and promotions. Although 10x Genomics's full-year earnings are still negative, it reduced its losses and improved its EPS by 7.4% annually over the last five years. The next few quarters will be critical for assessing its long-term profitability. In Q2, 10x Genomics reported EPS at $0.28, up from negative $0.32 in the same quarter last year. This print easily cleared analysts' estimates, and shareholders should be content with the results. Over the next 12 months, Wall Street expects 10x Genomics to perform poorly. Analysts forecast its full-year EPS of negative $0.70 will tumble to negative $1.01. Key Takeaways from 10x Genomics's Q2 Results We were impressed by how significantly 10x Genomics blew past analysts' EPS expectations this quarter. We were also excited its revenue outperformed Wall Street's estimates by a wide margin. On the other hand, its revenue guidance for next quarter missed. Zooming out, we think this was a good print with some key areas of upside. The stock traded up 7.9% to $13.79 immediately following the results. 10x Genomics had an encouraging quarter, but one earnings result doesn't necessarily make the stock a buy. Let's see if this is a good investment. If you're making that decision, you should consider the bigger picture of valuation, business qualities, as well as the latest earnings. We cover that in our actionable full research report which you can read here, it's free. Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
The Verge
41 minutes ago
- The Verge
Anyone can try Copilot 3D right now.
Posted Aug 8, 2025 at 11:34 AM UTC Anyone can try Copilot 3D right now. There are a variety of AI-powered tools to convert 2D images to 3D ones, but Microsoft has just introduced its own Copilot 3D feature that's free of charge. It converts images to the GLB format, which is compatible with 3D viewers, design tools, and game engines. Just be warned, it doesn't work well with animals or humans. Follow topics and authors from this story to see more like this in your personalized homepage feed and to receive email updates. Tom Warren Posts from this author will be added to your daily email digest and your homepage feed. See All by Tom Warren Posts from this topic will be added to your daily email digest and your homepage feed. See All AI Posts from this topic will be added to your daily email digest and your homepage feed. See All Microsoft Posts from this topic will be added to your daily email digest and your homepage feed. See All News Posts from this topic will be added to your daily email digest and your homepage feed. See All Tech
CNBC
an hour ago
- CNBC
Record-setting market: Using ETFs to help avoid hefty tax bills
A major exchange-traded fund provider is getting ready to launch a fund designed to ease investors' tax burdens from a record-setting stock market. Even though ETFs are considered more tax efficient than mutual funds, Astoria Portfolio Advisors plans to launch the Astoria U.S. Enhanced Core Equity ETF (LCOR) in October. The fund uses a tax-mitigation strategy that's known as an exchange or conversion under Section 351 of the tax code. When a stock has a huge run-up, investors may end up overconcentrated in that name, putting them on the hook for large capital gains taxes if they try to sell down the position. With a Section 351 exchange, investors may be able to reallocate some of that position without triggering capital gains taxes. They transfer those assets to a newly created ETF and receive shares of that fund in exchange. Bruce Lavine, the firm's chief operating officer and head of ETFs, thinks LCOR is particularly relevant as Big Tech's outperformance can leave investors with a pretty hefty tax bill if they take profits. "The idea behind a 351 fund is that you have a lot of stocks that get stuck from a tax perspective because they're up so much. Think about buying Nvidia two years ago. Perhaps you bought Microsoft 10 years ago," he told CNBC's "ETF Edge" this week. Based on Thursday's close, Nvidia has gained 83% over the past year, while Microsoft has jumped 31% in the same period. As of July 15, Big Tech stocks comprise one-third of the S&P 500, according to S&P Global. VettaFi Head of Research Todd Rosenbluth suggests Astoria is tapping into growing yearning for more tax efficiency. "ETFs in general are a tax-efficient vehicle, so you don't pay capital gains unless you're buying and selling," he said. "This is really focused for people who have a concentrated individual stock position and want to move that in instead of buying an ETF and holding it necessarily the same way."
